Xerostomia Market to Showcase Robust Growth in the Upcoming Years, asserts DelveInsight

 Breaking News
  • No posts were found

Xerostomia Market to Showcase Robust Growth in the Upcoming Years, asserts DelveInsight

June 06
18:50 2022
Xerostomia Market to Showcase Robust Growth in the Upcoming Years, asserts DelveInsight
Xerostomia Market

Xerostomia is defined as the “complaint of oral dryness”. It can occur due to inadequate salivary secretion secondary to abnormal function of the salivary glands, which is categorized as “true” xerostomia; however, most patients with xerostomia often do not have objective signs of hypo salivation. “Symptomatic” xerostomia or “pseudo” xerostomia refers to oral dryness despite normal salivary gland function.

 

DelveInsight’s “Xerostomia Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Xerostomia, historical and forecasted epidemiology as well as the Xerostomia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The causes of xerostomia may be divided into two broad categories: systemic diseases and local factors. Systemic diseases that can cause xerostomia include, but are not limited to, endocrine, autoimmune, infectious, and granulomatous diseases. The more common systemic diseases are reviewed here. Local factors that can cause xerostomia include medications, head and neck radiation therapy, and lifestyle factors.

 

Get Free Sample Copy of Report at: https://www.delveinsight.com/sample-request/xerostomia-market

 

Some facts of the Xerostomia Market are:

  • As per a study titled “Dry mouth treatment” (2018), Dry mouth (or xerostomia), a condition affectingmore than 80 million people in the high-income countries, is a chronic and mostly irreversible conditioninduced, mainly, as a side effect of hundreds of commonly used medications, by radiation therapy forhead & neck cancer, and by auto-immune diseases.
  • The above mentioned study also estimated the global market for dry mouth to be about USD 2 Billion.
  • The prevalence of xerostomia, of low stimulated salivary flow rate and low at rest salivary flow rate were 338 (38.8%), 494 (56.6%), 320 (36.7%), respectively in South Brazil. And important portion of the sample con ‐ currently presented xerostomia and salivary hypofunction (22.4%; n = 173). The sample included the average age of 68.5 ± 6.7 years, and the majority of the sample was comprised of women (65.3%).
  • The prevalence of hyposalivation and xerostomia in older persons. Its findings revealed a prevalence of 59.7% of hypos‐alivation and 25.2% of xerostomia, with 16.5% presenting both.
  • Xerostomia is more common in females than in males
  • Orellana et al. observed the prevalence of xerostomia ranged from 0.9% to 64.8%. The majority of data collected for these studies was in Scandinavia (most patients age greater than 50, the rest being over 18). [2006].

 

Some of Xerostomia Companies involved:

  • Lubris BioPharma
  • MeiraGTx UK II Ltd
  • GlaxoSmithKline PLC
  • Parnell Pharmaceuticals Inc.
  • Bausch Health Companies Inc.
  • Synedgen Inc. (Prisyna)
  • 3M company
  • And Many Others

 

Get Free Sample Copy of Report at: https://www.delveinsight.com/sample-request/xerostomia-market

 

Xerostomia therapies Covered:

  • LBS020
  • AAV-AQP1
  • And Many Others

 

Get Free Sample Copy of Report at: https://www.delveinsight.com/sample-request/xerostomia-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Xerostomia

3. Competitive Intelligence Analysis for Xerostomia

4. Xerostomia: Market Overview at a Glance

5. Xerostomia: Disease Background and Overview

6. Patient Journey

7. Xerostomia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Xerostomia Treatment

11. Marketed Products

12. Emerging Therapies

13. Xerostomia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Xerostomia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/xerostomia-market

Related Articles

Categories